Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05004025 | Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma | PHASE1 | COMPLETED | 10 | — | — | Feb 28, 2022 | Jul 23, 2025 | Aug 15, 2025 | 2 | United States |
evaluate the overall response rate of patients with mUM treated with TTF in combination with nivolumab and ipilimumab.
Evaluate the safety of TTF in combination with nivolumab and ipilimumab (Number of patients who developed grade 3 treatment-related adverse events as assessed by CTCAE v5)
| Arm | Type | Description |
|---|---|---|
| TTF Plus Chemotherapy | EXPERIMENTAL | Novacure Optune with Opdivo and Yervoy |
| Name | Type | Description |
|---|---|---|
| Novocure Optune | DEVICE | Novacure Optune with Opdivo and Yervoy |
| Opdivo | DRUG | Novacure Optune with Opdivo and Yervoy |
| Yervoy | DRUG | Novacure Optune with Opdivo and Yervoy |
Inclusion Criteria: 1. Patient has histologically or cytologically confirmed metastatic uveal melanoma with predominant liver involvement 2. Age 18 years or older and willing and able to provide informed consent 3. WOCBP must have a negative serum pregnancy test documented with 72 hours of first ad...